JNJ is up nearly 12% YTD as strong oncology drug growth, MedTech demand and pipeline advances help offset Stelara patent-loss ...

Johnson & Johnson recently launched Stelara for the treatment of adult patients with moderate to severe plaque psoriasis. Although Stelara is entering a crowded treatment room for psoriasis, this ...

Under assault from newer therapies in the anti-inflammatory market, Johnson & Johnson has focused on expanding Stelara beyond dermatology—and Monday, it took another big step in that direction. The ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...

Johnson & Johnson's immunology superstar Stelara and oncology blockbuster Darzalex have long been among the company's top revenue contributors. Now, with biosimilar and Inflation Reduction Act ...

The approval is supported by evidence from adequate and well-controlled studies of Stelara. The Food and Drug Administration (FDA) has expanded the approval of Stelara ® (ustekinumab) to include ...

WASHINGTON — Ninety-eight days may end up costing Johnson & Johnson. When Medicare this week announced the first 10 medicines that will be included in its brand-new drug price negotiation program, a J ...

Evernorth's Accredo specialty pharmacy will offer biosimilars for the popular immunotherapy Stelara at $0 for eligible patients, the company announced Thursday. The interchangeable biosimilar will be ...

The Biden administration has released the first 10 drugs subject to price negotiation with Medicare under the Inflation Reduction Act (IRA), and among those chosen were Stelara (ustekinumab) and ...

J&J seeks preliminary injunction over Samsung's sublicense deal with private label provider J&J says said sublicense deal would hurt its market share Samsung Bioepis launched its biosimilar in U.S. on ...

Johnson & Johnson’s (NYSE:JNJ) Stelara could become the #2 drug in the Crohn’s Disease market over the next few years. Crohn’s Disease causes inflammation of the digestive tract. J&J’s top selling ...